U.S. markets closed
  • S&P Futures

    4,656.75
    +5.75 (+0.12%)
     
  • Dow Futures

    35,150.00
    +73.00 (+0.21%)
     
  • Nasdaq Futures

    16,394.50
    +3.75 (+0.02%)
     
  • Russell 2000 Futures

    2,250.30
    +10.10 (+0.45%)
     
  • Crude Oil

    70.64
    +0.69 (+0.99%)
     
  • Gold

    1,790.10
    +4.90 (+0.27%)
     
  • Silver

    22.93
    +0.08 (+0.34%)
     
  • EUR/USD

    1.1305
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • Vix

    22.96
    -5.66 (-19.78%)
     
  • GBP/USD

    1.3325
    +0.0013 (+0.10%)
     
  • USD/JPY

    113.6600
    +0.0520 (+0.05%)
     
  • BTC-USD

    56,937.81
    -383.61 (-0.67%)
     
  • CMC Crypto 200

    1,435.51
    +6.58 (+0.46%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,498.91
    +214.99 (+0.76%)
     

Calculating The Fair Value Of USANA Health Sciences, Inc. (NYSE:USNA)

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of USANA Health Sciences, Inc. (NYSE:USNA) by taking the expected future cash flows and discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Believe it or not, it's not too difficult to follow, as you'll see from our example!

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

See our latest analysis for USANA Health Sciences

Is USANA Health Sciences fairly valued?

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) forecast

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Levered FCF ($, Millions)

US$127.6m

US$119.6m

US$115.1m

US$112.8m

US$111.8m

US$111.8m

US$112.4m

US$113.6m

US$115.0m

US$116.7m

Growth Rate Estimate Source

Est @ -9.74%

Est @ -6.23%

Est @ -3.77%

Est @ -2.05%

Est @ -0.85%

Est @ -0.01%

Est @ 0.58%

Est @ 1%

Est @ 1.29%

Est @ 1.49%

Present Value ($, Millions) Discounted @ 6.2%

US$120

US$106

US$96.0

US$88.5

US$82.6

US$77.8

US$73.7

US$70.0

US$66.8

US$63.8

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$845m

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.2%.

Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$117m× (1 + 2.0%) ÷ (6.2%– 2.0%) = US$2.8b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$2.8b÷ ( 1 + 6.2%)10= US$1.5b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$2.4b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of US$96.8, the company appears about fair value at a 18% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
dcf

The assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at USANA Health Sciences as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.2%, which is based on a levered beta of 0.975. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For USANA Health Sciences, we've put together three further aspects you should explore:

  1. Risks: For instance, we've identified 2 warning signs for USANA Health Sciences (1 doesn't sit too well with us) you should be aware of.

  2. Future Earnings: How does USNA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.